Engineered Immune Cells Show Promise Against Advanced Cancer in Early Trial
Scientists modified patients' immune cells to better recognize and attack cancer tumors expressing NY-ESO-1 protein.
20 articles
Scientists modified patients' immune cells to better recognize and attack cancer tumors expressing NY-ESO-1 protein.
Researchers modified children's own immune cells to fight B-cell leukemia and lymphoma when standard treatments failed.
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
A randomized Phase 2 trial investigates whether PD-1 inhibitor discontinuation after early response is safe in non-small cell lung cancer.
Innovative immunotherapy approach converts patient tumor cells into personalized vaccines to fight aggressive brain cancer.
French researchers studied how tiny cellular packages called exosomes may help melanoma cells resist treatment and spread throughout the body.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
Researchers tracked immune changes during intensive radiation treatment to optimize cancer therapy and potential immunotherapy combinations.
Small trial tests innovative treatment IBI346 for blood cancer patients who didn't respond to standard therapies.
A City of Hope study explores whether skin bacteria differ between rash-affected and healthy skin in cancer immunotherapy patients.
Study examines bone density loss in melanoma patients receiving immune-boosting cancer drugs like nivolumab and pembrolizumab.
Modified immune cells targeting GD2 protein demonstrated safety in treating aggressive childhood cancers like neuroblastoma and osteosarcoma.
A phase I/II trial tests SV-BR-1-GM, a whole-cell cancer vaccine, combined with the checkpoint inhibitor retifanlimab in patients with metastatic breast cancer.
Phase 2 trial explores whether combining oncolytic virus therapy with immunotherapy can rescue patients whose melanoma progressed on PD-1 blockade.
A phase I/II trial combining nivolumab, ipilimumab, and lurbinectedin for relapsed SCLC was terminated early, raising questions about feasibility.
A Phase 1/2 trial explores combining KIR, PD-1, and CTLA-4 inhibitors to unlock stronger anti-tumor immunity.
Phase II trial tests checkpoint inhibitors given before surgery to shrink tumors and improve outcomes in stage III-IV melanoma patients.
Italian researchers track genomic and cellular changes in myeloma patients to uncover why anti-CD38 treatments stop working.
Pfizer's first-in-human trial of PF-07209960, a dual-action immunotherapy fusion protein, was terminated after enrolling 37 patients.